mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome TherapeuticsMunich, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- mbiomics GmbH, a pioneering techbio company advancing scalable microbiome-based therapeutics for severe and chronic diseases, today announced the successful third closing of its Series A round at €12 million, bringing the total round size to €30 million. The financing round includes participation from existing investors including MIG Fonds and Bayern Kapital.
